Equities analysts forecast that Mesoblast limited (NASDAQ:MESO) will report earnings per share of ($0.25) for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Mesoblast’s earnings. Mesoblast reported earnings per share of ($0.22) during the same quarter last year, which would suggest a negative year over year growth rate of 13.6%. The company is expected to issue its next quarterly earnings report on Thursday, May 30th.
According to Zacks, analysts expect that Mesoblast will report full year earnings of ($0.92) per share for the current fiscal year, with EPS estimates ranging from ($1.00) to ($0.86). For the next year, analysts expect that the firm will report earnings of ($0.94) per share, with EPS estimates ranging from ($1.15) to ($0.72). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Mesoblast.
Mesoblast (NASDAQ:MESO) last issued its quarterly earnings data on Wednesday, February 20th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.06). The business had revenue of $1.87 million for the quarter, compared to the consensus estimate of $6.36 million. Mesoblast had a negative net margin of 528.80% and a negative return on equity of 15.98%.
Several equities analysts recently weighed in on the stock. Zacks Investment Research lowered shares of Mesoblast from a “buy” rating to a “hold” rating in a research report on Wednesday, April 3rd. ValuEngine raised shares of Mesoblast from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. HC Wainwright reiterated a “buy” rating on shares of Mesoblast in a report on Friday, February 22nd. Finally, Maxim Group reiterated a “buy” rating and set a $16.00 price target on shares of Mesoblast in a report on Thursday, February 21st. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $13.10.
Shares of MESO opened at $5.74 on Friday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.89 and a current ratio of 2.89. Mesoblast has a twelve month low of $3.35 and a twelve month high of $8.78.
A number of hedge funds have recently made changes to their positions in the business. Capital World Investors acquired a new position in Mesoblast during the third quarter valued at approximately $3,695,000. Penbrook Management LLC grew its holdings in Mesoblast by 6.2% during the fourth quarter. Penbrook Management LLC now owns 240,900 shares of the company’s stock valued at $993,000 after purchasing an additional 14,000 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of Mesoblast by 249.8% in the third quarter. Renaissance Technologies LLC now owns 165,161 shares of the company’s stock worth $1,348,000 after acquiring an additional 117,951 shares during the last quarter. Jane Street Group LLC grew its stake in shares of Mesoblast by 590.9% in the fourth quarter. Jane Street Group LLC now owns 104,073 shares of the company’s stock worth $426,000 after acquiring an additional 89,010 shares during the last quarter. Finally, Citadel Advisors LLC acquired a new stake in shares of Mesoblast in the third quarter worth $215,000. Institutional investors own 2.85% of the company’s stock.
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.
Further Reading: What is the Coverage Ratio?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.